Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Bavarian Nordic AS's
Operating Income
for the
three
months ended in Mar. 2026 was kr-7 Mil. Bavarian Nordic AS's Interest Expense for the
three
months ended in Mar. 2026 was kr-1 Mil.
did not have earnings to cover the interest expense.
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Ben Graham prefers companies' interest coverage to be at least 5. Bavarian Nordic AS has enough cash to cover all of its debt. Its financial situation is stable.
The historical rank and industry rank for Bavarian Nordic AS's Interest Coverage or its related term are showing as below:
CHIX:BAVAc'
s Interest Coverage Range Over the Past 10 Years
Min: 2.14 Med: 13.16 Max: 235.46
Current: 235.46
CHIX:BAVAc's Interest Coverage is ranked better than 54.64% of 377
companies
in the Biotechnology industry
Industry Median: 106.07
vs CHIX:BAVAc: 235.46
Bavarian Nordic AS (CHIX:BAVAc) Interest Coverage Explanation
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Bavarian Nordic AS Interest Coverage Related Terms
Bavarian Nordic AS Interest Coverage Historical Data
* Premium members only.
The historical data trend for Bavarian Nordic AS's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
CHIX:BAVAC vs VRTX, REGN, ALNY: Interest Coverage Comparison
For the Biotechnology subindustry, Bavarian Nordic AS's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bavarian Nordic AS Interest Coverage vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Bavarian Nordic AS's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Bavarian Nordic AS's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
Bavarian Nordic AS did not have earnings to cover the interest expense.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Interest Coverage of 0 (At Loss) mean?
Bavarian Nordic AS (CHIX:BAVAC) has a Interest Coverage of 0 (At Loss) as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Bavarian Nordic AS and its competitors. Over the past decade, Bavarian Nordic AS's Interest Coverage has ranged from 2.14 to 235.46. According to the industry distribution chart, Bavarian Nordic AS ranks #171 out of 377 companies in the Biotechnology industry, placing it in the top 45.4%.
Is Bavarian Nordic AS's Interest Coverage too high?
Bavarian Nordic AS's current Interest Coverage is 0 (At Loss). Over the past 10 years, this metric has ranged from a low of 2.14 to a high of 235.46. Based on the distribution chart, Bavarian Nordic AS ranks #171 out of 377 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Bavarian Nordic AS has a GF Score™ of 84/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Bavarian Nordic AS's Interest Coverage compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Bavarian Nordic AS ranks #171 out of 377 companies for Interest Coverage. This puts Bavarian Nordic AS in the upper half of its industry. The industry median Interest Coverage is 106.07. Historically, Bavarian Nordic AS's own Interest Coverage has ranged from 2.14 to 235.46 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Biotechnology company?
The median Interest Coverage among Biotechnology companies is 106.07, based on 377 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Bavarian Nordic AS and its competitors. For the Biotechnology industry, the median Interest Coverage is 106.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bavarian Nordic AS's current Interest Coverage is 0 (At Loss). However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bavarian Nordic AS stock overvalued right now?
Based on GuruFocus' analysis, Bavarian Nordic AS (CHIX:BAVAC) is currently considered Modestly Overvalued. The stock's GF Value™ is kr162.46, compared to a current price of kr188.30 — trading 15.9% above its estimated fair value. The current Interest Coverage is 0 (At Loss). Bavarian Nordic AS's overall GF Score™ is 84/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Bavarian Nordic AS (CHIX:BAVAC), the current Interest Coverage is 0 (At Loss) as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bavarian Nordic AS (CHIX:BAVAC) Overvalued in 2026?
Based on GuruFocus' analysis, Bavarian Nordic AS stock appears to be overvalued.
The current stock price of kr188.30 is trading 15.9% above its estimated GF Value™ of kr162.46.
GuruFocus considers Bavarian Nordic AS to be Modestly Overvalued.
Key valuation signals for CHIX:BAVAC:
Interest Coverage: 0 (At Loss)
GF Value™: kr162.46 vs. price of kr188.30 (15.9% above fair value)
No single metric tells the full story. See the CHIX:BAVAC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bavarian Nordic AS is a biotechnology company focused on the research, development, manufacturing, and commercialization of life-saving vaccines. The group is a supplier of mpox and smallpox vaccines to governments to enhance public health preparedness and has a portfolio of travel vaccines. The vast majority of the company's revenue is generated in the United States, Germany, and other geographic markets. Its products include Encepur, Jynneos, Rabipur, Vaxchora, VIMKUNYA and Vivotif.
84GF Score
Get the complete analysis for CHIX:BAVAC
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:BAVAC has been successfully added to your 
